131 related articles for article (PubMed ID: 2108884)
1. Luteinizing hormone releasing hormone agonists: the US experience.
Nabors W; Crawford ED
J Int Med Res; 1990; 18 Suppl 1():31-4. PubMed ID: 2108884
[TBL] [Abstract][Full Text] [Related]
2. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
Crawford ED; Goodman P; Blumenstein B
Semin Urol; 1990 Aug; 8(3):154-8. PubMed ID: 2119048
[No Abstract] [Full Text] [Related]
3. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
[TBL] [Abstract][Full Text] [Related]
4. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo.
Benson RC; Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Dorr FA
Semin Oncol; 1991 Oct; 18(5 Suppl 6):9-12. PubMed ID: 1948121
[TBL] [Abstract][Full Text] [Related]
5. Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
Kung TT; Mingo GG; Siegel MI; Watnick AS
Prostate; 1988; 12(4):357-63. PubMed ID: 3134647
[TBL] [Abstract][Full Text] [Related]
6. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
Navratil H
J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
[TBL] [Abstract][Full Text] [Related]
7. Flutamide approved for prostate cancer.
Oncology (Williston Park); 1989 Mar; 3(3):135. PubMed ID: 2518157
[No Abstract] [Full Text] [Related]
8. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
Labrie F; Dupont A; Belanger A; Lachance R
J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
[TBL] [Abstract][Full Text] [Related]
9. Leuprolide plus flutamide: combined androgen blockade in the treatment of advanced prostate cancer.
Chodoff L
Mt Sinai J Med; 1990 May; 57(3):171-3. PubMed ID: 2115128
[No Abstract] [Full Text] [Related]
10. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
Crawford ED; Allen JA
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):961-3. PubMed ID: 2126738
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
12. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group.
Bischoff W
J Int Med Res; 1990; 18 Suppl 1():103-13. PubMed ID: 2108882
[TBL] [Abstract][Full Text] [Related]
13. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial.
Rizzo M; Mazzei T; Mini E; Bartoletti R; Periti P
J Int Med Res; 1990; 18 Suppl 1():114-25. PubMed ID: 2108883
[TBL] [Abstract][Full Text] [Related]
14. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
Tsushima T; Nasu Y; Saika T; Maki Y; Noda M; Suyama B; Yamato T; Kumon H
Urol Int; 2001; 66(3):135-9. PubMed ID: 11316974
[TBL] [Abstract][Full Text] [Related]
15. Flutamide for prostate cancer.
Med Lett Drugs Ther; 1989 Jul; 31(797):72. PubMed ID: 2501635
[No Abstract] [Full Text] [Related]
16. Combination studies with leuprolide.
Crawford ED
Eur Urol; 1990; 18 Suppl 3():30-3. PubMed ID: 2128828
[TBL] [Abstract][Full Text] [Related]
17. Leuprolide with and without flutamide in advanced prostate cancer.
Crawford ED; Blumenstein BA; Goodman PJ; Davis MA; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA
Cancer; 1990 Sep; 66(5 Suppl):1039-44. PubMed ID: 2118417
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer.
O' Brien A; Hibberd M
J Int Med Res; 1990; 18 Suppl 1():57-68. PubMed ID: 2108886
[TBL] [Abstract][Full Text] [Related]
19. [Total androgen blockade].
Namiki M; Mizokami A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
[No Abstract] [Full Text] [Related]
20. Flutamide: an antiandrogen for advanced prostate cancer.
Goldspiel BR; Kohler DR
DICP; 1990 Jun; 24(6):616-23. PubMed ID: 2193461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
